Pancreatic Cancer

• CLINICAL_TRIALS withdrawal · 2026-04-13
  Clinical Trial Update: Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle [NA]

  A clinical trial comparing Beacon BNX EUS-Needle vs SharkCore Needle has been withdrawn. The study involved pancreatic cancer, lymphadenopat…

• CLINICAL_TRIALS withdrawal · 2026-03-27
  Clinical Trial Update: EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients [NA]

  The EpiDetect study, a clinical trial validating a pancreatic cancer detection test in patients with new-onset diabetes, has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2026-02-11
  Clinical Trial Update: Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cancer. [NA]

  A clinical trial evaluating nutritional supplementation to improve quality of life in locally advanced or metastatic pancreatic cancer was w…

• CLINICAL_TRIALS withdrawal · 2025-11-18
  Clinical Trial Update: FOLFIRINOX + NIS793 in Pancreatic Cancer [Phase 1]

  A Phase 1 trial evaluating the combination of FOLFIRINOX and NIS793 in pancreatic cancer has been terminated.

• CLINICAL_TRIALS withdrawal · 2025-11-17
  Clinical Trial Update: A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer [Phase 2]

  A Phase II study evaluating GFH375 in KRAS G12D-mutant metastatic pancreatic cancer has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2025-09-11
  Clinical Trial Update: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies [Phase 2]

  A Phase II clinical trial investigating adjuvant immunotherapy targeting KRAS G12D, KRAS G12V, and TP53 R175H across several gastrointestina…

• CLINICAL_TRIALS withdrawal · 2025-09-04
  Clinical Trial Update: PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 [Phase 1]

  Phase 1 trial evaluating PET imaging agents 64Cu-Tz-SarAr and hu5B1-TCO in pancreatic, colorectal, and bladder cancers (including cancers wi…

• CLINICAL_TRIALS withdrawal · 2025-07-30
  Clinical Trial Update: HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

  Alaunos Therapeutics reports termination of a Phase I/II autologous TCR-T cell trial across several solid tumors. The study focused on HLA t…

• CLINICAL_TRIALS withdrawal · 2025-07-25
  Clinical Trial Update: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients [Phase 1]

  A Phase Ib trial evaluating the KRAS G12C inhibitor adagrasib in KRAS G12C mutant metastatic pancreatic cancer has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2025-07-11
  Clinical Trial Update: A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer [Phase 2]

  A Phase 2 trial evaluating gemcitabine, pembrolizumab, and IMM-101 as first-line therapy for metastatic pancreatic cancer has been withdrawn…

• CLINICAL_TRIALS withdrawal · 2025-06-25
  Clinical Trial Update: TCR1020-CD8 T Cells in KRAS-mutated Cancers [Phase 1]

  Phase 1 study of TCR1020-CD8 T cells for KRAS-mutated cancers has been withdrawn, involving metastatic pancreatic cancer and colorectal canc…

• CLINICAL_TRIALS withdrawal · 2025-06-06
  Clinical Trial Update: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC [Phase 1, Phase 2]

  Lisata Therapeutics reports that the Phase 1b/2a continuous infusion trial of ceretpetide in pancreatic ductal adenocarcinoma has been withd…

• CLINICAL_TRIALS withdrawal · 2025-04-09
  Clinical Trial Update: Study of OB-002 in Patients With Refractory Metastatic Cancer [Phase 1]

  Phase 1 study of OB-002 in various metastatic cancers has been withdrawn from clinical trials.

• CLINICAL_TRIALS withdrawal · 2025-03-18
  Clinical Trial Update: TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors [Phase 1, Phase 2]

  Tarus Therapeutics has withdrawn its TT-4 single-agent trial in advanced solid tumors across Phase 1 and Phase 2. The listed conditions incl…

• CLINICAL_TRIALS withdrawal · 2025-03-10
  Clinical Trial Update: A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients [Phase 2]

  A Phase 2 clinical trial evaluating pharmacological ascorbate in combination with radiation therapy for pancreatic cancer has been withdrawn…

• CLINICAL_TRIALS withdrawal · 2025-02-21
  Clinical Trial Update: QUILT-3.088: NANT Pancreatic Cancer Vaccine [Phase 2]

  A Phase 2 trial of the NANT Pancreatic Cancer Vaccine (QUILT-3.088) for metastatic pancreatic cancer has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2025-01-24
  Clinical Trial Update: Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers [Phase 1]

  Phase 1 trial evaluating the combination of RMC-4630 and LY3214996 in metastatic KRAS-mutant cancers has been terminated. The study encompas…

• CLINICAL_TRIALS withdrawal · 2024-12-27
  Clinical Trial Update: GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer [Phase 2]

  A Phase 2 trial of gemcitabine plus nab-paclitaxel and losartan followed by stereotactic radiotherapy for locally advanced pancreatic cancer…

• CLINICAL_TRIALS withdrawal · 2024-12-09
  Clinical Trial Update: Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer [NA]

  This clinical trial (NCT04136769) evaluating preoperative/neoadjuvant therapy with vascular debranching followed by resection for locally ad…

• CLINICAL_TRIALS withdrawal · 2024-11-25
  Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

  A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…

• CLINICAL_TRIALS withdrawal · 2024-10-26
  Clinical Trial Update: An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study [NA]

  A clinical trial evaluating an exercise and nutrition monitoring intervention for strengthening patients with gastric or pancreatic cancer u…

• CLINICAL_TRIALS withdrawal · 2024-10-26
  Clinical Trial Update: Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver [Phase 1, Phase 2]

  The clinical trial NCT05610826 comparing preoperative PRRT to surgical cytoreduction for metastatic pancreatic neuroendocrine tumors to the …

• CLINICAL_TRIALS withdrawal · 2024-09-19
  Clinical Trial Update: A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer [Phase 2]

  A Phase 2 trial evaluating a nutritional supplement for pancreatic cancer has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2024-08-21
  Clinical Trial Update: Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study [NA]

  A clinical trial evaluating mesothelin-targeted CAR-T cells as neoadjuvant therapy for resectable pancreatic cancer has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2024-08-15
  Clinical Trial Update: Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer [Phase 2]

  The Phase 2 trial evaluating devimistat in combination with mFFX for second-line metastatic pancreatic cancer was withdrawn.